Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 5/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | STAT3 | P40763 | 1/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL9105695 | 0.93 | ALOX5 (0.36) | BCHEALOX5HTTALDH1A1LMNA | |
| SCHEMBL9104042 | 0.85 | HTT (0.38) | BCHENPC1RAB9AMEN1AGTR1 | |
| SCHEMBL9106544 | 0.81 | MAPT (0.39) | HTTLMNASMN1; SMN2CRHR1MAPT | |
| Sulfuric Acid SCHEMBL9102391 | 0.79 | ALOX5 (0.35) | BCHEALOX5HTTALDH1A1LMNA | |
| SCHEMBL9100755 | 0.76 | MAPT (0.35) | HTTSMN1; SMN2CRHR1MAPT | |
| SCHEMBL9102473 | 0.74 | MAPT (0.36) | ALDH1A1HPGDSMN1; SMN2CRHR1MAPT | |
| Sulfuric Acid SCHEMBL9108729 | 0.74 | MAPT (0.33) | SMN1; SMN2MAPT | |
| SCHEMBL9102467 | 0.73 | MAPT (0.37) | HTTSMN1; SMN2CRHR1MAPT | |
| Sulfuric Acid SCHEMBL9108758 | 0.70 | MAPT (0.31) | SMN1; SMN2MAPT | |
| SCHEMBL9107263 | 0.70 | MAPT (0.42) | NPC1RAB9AMEN1AGTR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160256463-A1 | NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS INC (US) | 2016-09-08 | — | — | US | claimed |
| US-9351972-B2 | Compounds as respiratory stimulants for treatment of breathing control disorders or diseases | GALLEON PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | claimed |
| US-20120142647-A1 | Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases | GALLEON PHARMACEUTICALS, INC. | 2012-06-07 | — | — | US | claimed |
| US-20260137675-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT DRUG OVERDOSE | ENALARE THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12544369-B2 | Methods and pharmaceutical compositions to treat drug overdose | ENALARE THERAPEUTICS INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250325554-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT RESPIRATORY DEPRESSION IN PATIENTS | ENALARE THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250114370-A1 | METHODS AND COMPOSITIONS FOR TREATING DRUG OVERDOSE | ENALARE THERAPEUTICS INC (US) | 2025-04-10 | — | — | US | disclosed |
| US-20250032496-A1 | METHODS OF TREATING RESPIRATORY DEPRESSION MODULATED BY A NON-OPIOID AGENT | ENALARE THERAPEUTICS INC (US) | 2025-01-30 | — | — | US | disclosed |
| US-12138267-B2 | Methods of treating respiratory depression modulated by a non-opioid agent | ENALARE THERAPEUTICS INC. (US) | 2024-11-12 | — | — | US | disclosed |
| US-20240238303-A1 | LARGE-CONDUCTANCE POTASSIUM CHANNEL MODULATORS, COMPOSITIONS THEREOF, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF | ENALARE THERAPEUTICS INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-20230414624-A1 | METHODS OF TREATING NEUROLOGICAL VENTILATORY INSUFFICIENCY | ENALARE THERAPEUTICS INC (US) | 2023-12-28 | — | — | US | disclosed |
| US-20230310440-A1 | RESPIRATORY STIMULANT NASAL FORMULATIONS | ENALARE THERAPEUTICS INC. | 2023-10-05 | — | — | US | disclosed |
| WO-2023192602-A2 | RESPIRATORY STIMULANT NASAL FORMULATIONS | ENALARE THERAPEUTICS INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230210857-A1 | RESPIRATORY STIMULANT PARENTERAL FORMULATIONS | ENALARE THERAPEUTICS INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230140606-A1 | METHODS OF TREATING RESPIRATORY DEPRESSION MODULATED BY A NON-OPIOID AGENT | ENALARE THERAPEUTICS INC. | 2023-05-04 | — | — | US | disclosed |
| US-20220241268-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT DRUG OVERDOSE | ENALARE THERAPEUTICS INC. | 2022-08-04 | — | — | US | disclosed |
| CN-114173872-A | Methods and pharmaceutical compositions for treating drug overdose | 依那拉治疗股份有限公司 | 2022-03-11 | — | — | CN | disclosed |
| US-20160256463-A1 | NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS INC (US) | 2016-09-08 | — | — | US | disclosed |
| US-9351972-B2 | Compounds as respiratory stimulants for treatment of breathing control disorders or diseases | GALLEON PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20120142647-A1 | Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases | GALLEON PHARMACEUTICALS, INC. | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12544369-B2 | Methods and pharmaceutical compositions to treat drug overdose | OPRK1, OPRD1, OPRM1 | BCHE 815/4885NPC1 799/4885RAB9A 2670/4885 |
| US-20120142647-A1 | Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases | MTNR1B, CHRM3, ADRA2C | BCHE 119/4885NPC1 1934/4885RAB9A 2226/4885 |
| US-12138267-B2 | Methods of treating respiratory depression modulated by a non-opioid agent | OPRK1, OPRM1, OPRD1 | BCHE 564/4885NPC1 3853/4885RAB9A 2969/4885 |
| US-20260137675-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT DRUG OVERDOSE | ADRA2B, ADRB1, ADRB2 | BCHE 733/4885NPC1 1792/4885RAB9A 1495/4885 |
| US-20250325554-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT RESPIRATORY DEPRESSION IN PATIENTS | NDUFB6, NDUFB7, CHRM5 | BCHE 232/4885NPC1 2688/4885RAB9A 3334/4885 |
| US-20250032496-A1 | METHODS OF TREATING RESPIRATORY DEPRESSION MODULATED BY A NON-OPIOID AGENT | OPRK1, OPRM1, OPRD1 | BCHE 564/4885NPC1 3853/4885RAB9A 2969/4885 |
| US-20230310440-A1 | RESPIRATORY STIMULANT NASAL FORMULATIONS | ADRA2C, MTNR1B, MTNR1A | BCHE 1505/4885NPC1 806/4885RAB9A 2293/4885 |
| US-20160256463-A1 | NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | P2RX5, HRH2, ADRA2C | BCHE 591/4885NPC1 2911/4885RAB9A 3393/4885 |
| US-20230140606-A1 | METHODS OF TREATING RESPIRATORY DEPRESSION MODULATED BY A NON-OPIOID AGENT | OPRK1, OPRM1, OPRD1 | BCHE 564/4885NPC1 3853/4885RAB9A 2969/4885 |
| US-20220241268-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT DRUG OVERDOSE | OPRK1, OPRM1, ADRB1 | BCHE 349/4885NPC1 1851/4885RAB9A 1917/4885 |
| US-20250114370-A1 | METHODS AND COMPOSITIONS FOR TREATING DRUG OVERDOSE | ADRA2A, ADRA2C, OPRM1 | BCHE 342/4885NPC1 1273/4885RAB9A 2958/4885 |
| US-20240238303-A1 | LARGE-CONDUCTANCE POTASSIUM CHANNEL MODULATORS, COMPOSITIONS THEREOF, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF | KCNN2, KCNN1, KCNN3 | BCHE 3949/4885NPC1 766/4885RAB9A 3139/4885 |
| US-20230210857-A1 | RESPIRATORY STIMULANT PARENTERAL FORMULATIONS | ADRA2C, ADRA1B, CHRM3 | BCHE 503/4885NPC1 2226/4885RAB9A 2333/4885 |
| US-20230414624-A1 | METHODS OF TREATING NEUROLOGICAL VENTILATORY INSUFFICIENCY | SDHA, NDUFB7, OTC | BCHE 122/4885NPC1 1099/4885RAB9A 3318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.